Pfizer acquires 40% stake in Brazilian generics firm Teuto
This article was originally published in Scrip
Pfizer says it is aiming to boost its presence in Brazil by acquiring a 40% stake in the local generics firm Teuto, in a deal worth an initial $240 million. Through the agreement, the two companies will develop and commercialise generic medicines, said Pfizer.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.